FMK

• Description:

  FMK is a an irreversible RSK2 kinase inhibitor, that covalently modifies the C-terminal kinase domain of RSK.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Ribosomal S6 Kinase (RSK)

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/FMK.html

• Concentration:

  10mM

• Purity:

  99.83

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  FCC(C1=C(C2=C(N=CN=C2N1CCCO)N)C3=CC=C(C=C3)C)=O

• Molecular Formula:

  C18H19FN4O2

• Molecular Weight:

  342.37

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Cuello F, et al. Evidence for direct regulation of myocardial Na+/H+ exchanger isoform 1 phosphorylation and activity by 90-kDa ribosomal S6 kinase (RSK) : effects of the novel and specific RSK inhibitor fmk on responses to alpha1-adrenergic stimulation.|[2]Bain J, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408 (3) :297-315.|[3]Kang S, et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell. 2007 Sep;12 (3) :187-9.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  RSK2

• CAS Number:

  821794-92-7